{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifwvvaqip2bbglbef3jvniq3j4bewm5e73z6bfm4muokpumjwqrqu",
    "uri": "at://did:plc:amgpmo7quvdl4rzvmmjibtx6/app.bsky.feed.post/3mksv76u5efg2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidsem3oaowrbgw64v5rxkifm2npfkf6b6dgswmjsladhxqkc2t6qi"
    },
    "mimeType": "image/jpeg",
    "size": 542148
  },
  "path": "/2026/05/01/business/fda-pancreatic-cancer-drug.html",
  "publishedAt": "2026-05-01T16:17:14.000Z",
  "site": "https://www.nytimes.com",
  "tags": [
    "Drugs (Pharmaceuticals)",
    "Pancreatic Cancer",
    "Pancreas",
    "Clinical Trials",
    "Regulation and Deregulation of Industry",
    "United States Politics and Government",
    "Chemotherapy",
    "Food and Drug Administration",
    "Sasse, Benjamin E",
    "Trump, Donald J"
  ],
  "textContent": "Patients with one of the deadliest cancers have been pleading for an unapproved treatment that may prolong their lives.",
  "title": "F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer"
}